Nepafenac Once Daily for Macular Edema - Study 2

Inclusion Criteria:

• Planned cataract extraction by phacoemulsification with implantation of a posteriorchamber intraocular lens;

• History of Type 1 or 2 diabetes and non-proliferative diabetic retinopathy (NPDR) (mild, moderate, or severe) in the study eye;

• Best-corrected visual acuity (BCVA) of 73 letters or worse in the study eye withexpectation of improvement after surgery;

• Understand and sign an informed consent document;

• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Pre-existing macular edema in the study eye;

• History in the study eye of retinal detachment, wet age-related macular degeneration,chronic or recurrent inflammatory eye disease, or prior procedures;

• Planned cataract surgery in the fellow eye prior to the Day 90 postoperative studyvisit or through study exit;

• Planned multiple procedures for the study eye during the cataract/intraocular lens;

• Use of exclusionary medications, including nonsteroidal anti-inflammatory drugs (NSAIDs) and steroids, as specified in protocol.

• Participation in any other clinical study within 30 days of the screening visit;

• Females of childbearing potential who are breast feeding, have a positive urinepregnancy test at screening, are not willing to undergo a urine pregnancy test uponentering or exiting the study, intend to become pregnant during the study, or do notagree to use adequate birth control methods for the duration of the study;

• Other protocol-defined exclusion criteria may apply.